Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06926660 · ClinicalTrials.gov registry record · Phase 2

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

A Phase 2 study of Chronic Kidney Disease, sponsored by Boehringer Ingelheim.

Recruiting
Registry status
Phase 2
Development phase
416
Enrollment target
20
Study locations

NCT06926660: Recruiting Phase 2 study of Chronic Kidney Disease, sponsored by Boehringer Ingelheim.

NCT06926660 is a Phase 2 study of Chronic Kidney Disease that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 416 participants, below the 3,203-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06926660, a Phase 2 study of Chronic Kidney Disease, is actively recruiting participants, sponsored by Boehringer Ingelheim.

RECRUITING
Registry status
Phase 2
Development phase
416 participants
Enrollment target
20
Study locations

Study Summary

This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication for kidney disease called SGLT2 inhibitor within 1 month before the study or have certain health conditions cannot take part in this study. The purpose of this study is to find out whether a medicine called vicadrostat, used in combination with another medicine called empagliflozin, works in people with chronic kidney disease. In this study, participants are randomly assigned to one of two groups. Participants have an equal chance of being assigned to either group. In one group, participants take the 2 study medicines, vicadrostat and empagliflozin, every day for 3 months. In the other group, participants take placebo and empagliflozin for the first 1.5 months, and then they take vicadrostat and empagliflozin together for the next 1.5 months. The study medicines are taken orally as tablets. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants are in the study for about 4.5 months. During this time, they visit the study site multiple times. Doctors regularly test kidney function by measuring specific proteins in the blood and urine. The results are compared between the two groups to see whether there are differences between starting the study medicines at the same time or one after the other. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions Studied

Chronic Kidney Disease

Interventions

  • DRUG Empagliflozin
  • DRUG Vicadrostat
  • DRUG Placebo matching vicadrostat

Study Locations (20)

Florida

  • Clinical Research of Brandon LLC - Brandon
  • Hillcrest Medical Research - DeLand
  • Encore Medical Research - Hollywood
  • Finlay Medical Research Corp - Miami
  • Total Research Group, LLC - Miami
  • San Marcus Research Clinic, Inc. - Miami Lakes
  • West Orange Endocrinology - Ocoee
  • Florida Kidney Physicians - Riverview/Brandon - Riverview

California

  • Orange County Clinical Trials - Anaheim
  • North America Research Institute - San Dimas
  • Valiance Clinical Research-Tarzana-68237 - Tarzana
  • Amicis Research Center - Valencia - Valencia
  • Focus Clinical Research - West Hills

Illinois

  • Research by Design, LLC - Chicago
  • Nephrology Associates of Northern Illinois and Indiana - Oak Brook - Hinsdale

Alabama

  • Apogee Clinical Research - Huntsville

Georgia

  • Masters of Clinical Research, Inc - Augusta

Idaho

  • Boise Kidney and Hypertension, PLLC - Boise

Indiana

  • Nephrology Associates of Northern Illinois and Indiana - Fort Wayne - Fort Wayne

Kansas

  • Kansas Nephrology Research Institute, LLC - Wichita

Trial Details

FieldValue
Enrollment Target 416 participants
Start Date 2025-07-18
Est. Completion 2026-08-20
Phase Phase 2
Boehringer Ingelheim

515 total trials

What NCT06926660 shows while recruiting

NCT06926660 is an interventional study that assigns participants to a tested intervention. The registered 416 participants enrollment target is mid-sized for trials with a published cap, below the 3,203-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 3 interventions - of which Empagliflozin is the first listed.

NCT06926660 names 20 study sites across 8 states, led by Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT06926660 about?

NCT06926660 is a clinical study titled "A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease". This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication for kidney disease called SGLT2 inhibitor within 1 month before the study or have certain health conditions cannot take part in this study. The purpose...

What is the current status of trial NCT06926660?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 416 participants. The study started on 2025-07-18. Estimated completion is 2026-08-20.

What conditions does trial NCT06926660 study?

This clinical trial studies the following conditions: Chronic Kidney Disease.

What interventions are being tested in trial NCT06926660?

The interventions under investigation include: Empagliflozin (DRUG), Vicadrostat (DRUG), Placebo matching vicadrostat (DRUG).

Who is sponsoring clinical trial NCT06926660?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06926660 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06926660's enrollment target sits among peer trials

416 29th of 101 higher than 73 of 101 other Chronic Kidney Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03527537 · 416 participants · Phase 4

    Gestational Diabetes and Pharmacotherapy (GAP)

  • NCT05007782 · 416 participants · Phase 1

    Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

  • NCT05520099 · 416 participants

    Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

  • NCT06075745 · 416 participants · Phase 2

    Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06926660

Source: ClinicalTrials.gov NCT06926660, the US trial registry maintained by the National Library of Medicine. NCT06926660 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.